Due to the high concentration of chemotherapeutic drugs in the liver, patients in the triple combination therapy presented more AEs related to liver dysfunction, including elevated ALT, elevated AST, hypoalbuminemia, and hyperbilirubinemia. The gene discussed is GPT; the disease is Decreased liver function.